Intensity Therapeutics, Inc. announced on August 4, 2025, that it raised $6.6 million in gross proceeds, or $6.3 million net, through its At-the-Market (ATM) offering in July 2025. The company sold 19,868,658 shares of common stock at an average price of $0.3323 per share. This capital infusion significantly strengthens the company's balance sheet.
The proceeds from these ATM sales are projected to extend Intensity Therapeutics' cash runway into the second half of 2026. Lewis H. Bender, President and CEO, noted that the average price per share for these sales was over 10% higher than the recently completed June 2025 public offering, and the costs to raise this capital were lower.
This strategic capital raise addresses critical funding needs, allowing the company to continue advancing its clinical trials. The company plans to be selective and strategic in deploying the remainder of its ATM facility.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.